18 Aug 2016 07:00
For immediate release | 18 August 2016 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Interim Results Analyst Meeting - Change of Time
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will hold the analyst presentation of its results for the six months ended 30 June 2016 at the revised time of 10.30am on Wednesday 14 September 2016.
The presentation will be held at the offices of Buchanan, 107 Cheapside, London EC2V 6DN. For more information, or to register attendance, please contact Buchanan on 020 7466 5000.
For further information:
Alliance Pharma plc | + 44 (0) 1249 466966 |
John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer | |
Sarah Robinson, Company Secretary | |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Sophie Cowles / Jane Glover | |
Numis Securities Limited | + 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Freddie Barnfield | |
Corporate Broking: James Black / Toby Adcock |
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
Alliance Pharma (APH)